Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
NEW ORLEANS, Nov. 08, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 5, 2017 to file lead plaintiff applications in securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE:TEVA), if they purchased the Company’s American Depositary Shares between February 10, 2015 and November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you purchased shares of Teva and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 5, 2017.
About the Lawsuit
Teva and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Teva, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
